🧪 VHH therapies, which are single-domain antibodies, have advantages over large monoclonal antibodies in treating chronic diseases.
❌ Switching between different expression platforms has been a challenge for VHH therapies.
🔬Using baker’s yeast as the production strain for both discovery and manufacture can solve this problem.
🍞 Baker’s yeast lacks toxic endotoxins and is safer, faster, and more affordable than traditional approaches.
💪 With this technology, VHH discovery can be made more affordable, empowering research for complex diseases.
🌱 The use of baker’s yeast is regulatory-friendly, speeding up clinical development and commercial manufacture.
⏰ By shortening timeframes, VHH therapies can be more quickly available to patients.
Introduction:
The article discusses a new technology that uses baker’s yeast to transform the discovery and manufacture of VHH therapies. VHHs (Variable Heavy Chain Domains) are single-domain antibodies that have significant advantages over conventional monoclonal antibodies. However, the existing approach to VHH discovery and manufacture is associated with risks, costs, and long timelines. The use of baker’s yeast as a production strain allows for a seamless and more regulatory-friendly process, enabling the same strain to be used for both discovery and large-scale commercial manufacture.
- VHH therapies have significant advantages over conventional monoclonal antibodies in treating chronic diseases.
- The traditional approach to VHH discovery and manufacture involves switching between different expression platforms (E. coli and CHO), which is costly, slow, and presents technical risks.
- Baker’s yeast can be used as a production strain for VHHs, eliminating the need for switching expression platforms.
- The use of baker’s yeast is safer, faster, and more affordable, as it lacks the toxic endotoxins produced by E. coli.
- The technology allows for the quick establishment of a yeast strain’s ability to secrete the relevant VHH, reducing time, cost, and resource wastage.
Conclusion:
The use of baker’s yeast in VHH discovery and manufacture offers a transformative solution to the risks, costs, and long timelines associated with the traditional approach. This technology provides a safer, faster, and more affordable process, with the same production strain being used from discovery to large-scale commercial manufacture. By eliminating the need for switching expression platforms, it significantly streamlines the development and production of VHH therapies for chronic diseases.
